ABCL – AbCellera Biologics Inc.
Name : AbCellera Biologics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $0.0000
EPSttm :
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ABCL
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=ABCL
&conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]
Float Short %
10.57
Margin Of Safety %
Put/Call OI Ratio
0.2
EPS Next Q Diff
-0.03
EPS Last/This Y
-0.11
EPS This/Next Y
0.07
Price
2.42
Target Price
10.33
Analyst Recom
1.25
Performance Q
-17.69
Relative Volume
0.7
Beta
0.41
Ticker: ABCL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | ABCL | 2.38 | 0.20 | 0.05 | 28587 |
| 2025-03-21 | ABCL | 2.43 | 0.20 | 0.13 | 28522 |
| 2025-03-24 | ABCL | 2.6 | 0.19 | 1.74 | 25479 |
| 2025-03-25 | ABCL | 2.53 | 0.20 | 1.76 | 25663 |
| 2025-03-26 | ABCL | 2.43 | 0.21 | 0.00 | 25890 |
| 2025-03-27 | ABCL | 2.37 | 0.21 | 2.76 | 26028 |
| 2025-03-28 | ABCL | 2.3 | 0.21 | 1.04 | 26074 |
| 2025-03-31 | ABCL | 2.23 | 0.21 | 0.08 | 26239 |
| 2025-04-01 | ABCL | 2.09 | 0.21 | 0.05 | 26259 |
| 2025-04-02 | ABCL | 2.21 | 0.21 | 3.63 | 26478 |
| 2025-04-03 | ABCL | 2.09 | 0.21 | 1.35 | 26578 |
| 2025-04-04 | ABCL | 2.09 | 0.21 | 6.82 | 26600 |
| 2025-04-07 | ABCL | 2.05 | 0.22 | 1.55 | 26793 |
| 2025-04-08 | ABCL | 1.93 | 0.22 | 0.23 | 26742 |
| 2025-04-09 | ABCL | 2.16 | 0.22 | 0.16 | 26916 |
| 2025-04-10 | ABCL | 2.075 | 0.22 | 0.90 | 26850 |
| 2025-04-11 | ABCL | 2.39 | 0.20 | 0.32 | 26463 |
| 2025-04-14 | ABCL | 2.45 | 0.20 | 0.03 | 26811 |
| 2025-04-15 | ABCL | 2.43 | 0.19 | 0.48 | 27079 |
| 2025-04-16 | ABCL | 2.4 | 0.20 | 0.77 | 27122 |
| 2025-04-17 | ABCL | 2.42 | 0.20 | 0.60 | 27131 |
| 2025-04-18 | ABCL | 2.42 | 0.20 | 0.49 | 27131 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | ABCL | 2.38 | -1.8 | - | -0.66 |
| 2025-03-21 | ABCL | 2.44 | -1.8 | - | -0.66 |
| 2025-03-24 | ABCL | 2.59 | -1.8 | - | -0.66 |
| 2025-03-25 | ABCL | 2.53 | -1.8 | - | -0.66 |
| 2025-03-26 | ABCL | 2.42 | -1.8 | - | -0.66 |
| 2025-03-27 | ABCL | 2.37 | -1.8 | - | -0.66 |
| 2025-03-28 | ABCL | 2.31 | -1.8 | - | -0.66 |
| 2025-03-31 | ABCL | 2.23 | -1.8 | - | -0.66 |
| 2025-04-01 | ABCL | 2.09 | -1.8 | - | -0.66 |
| 2025-04-02 | ABCL | 2.22 | -1.8 | - | -0.66 |
| 2025-04-03 | ABCL | 2.08 | -1.8 | - | -0.66 |
| 2025-04-04 | ABCL | 2.09 | -1.8 | - | -0.66 |
| 2025-04-07 | ABCL | 2.04 | -1.8 | - | -0.66 |
| 2025-04-08 | ABCL | 1.93 | -1.8 | - | -0.66 |
| 2025-04-09 | ABCL | 2.16 | -1.8 | - | -0.66 |
| 2025-04-10 | ABCL | 2.09 | -1.8 | - | -0.66 |
| 2025-04-11 | ABCL | 2.40 | -1.8 | - | -0.66 |
| 2025-04-14 | ABCL | 2.44 | -1.8 | - | -0.66 |
| 2025-04-15 | ABCL | 2.43 | -1.8 | - | -0.66 |
| 2025-04-16 | ABCL | 2.40 | -1.8 | - | -0.66 |
| 2025-04-17 | ABCL | 2.42 | -1.8 | - | -0.66 |
| 2025-04-18 | ABCL | 2.42 | -1.8 | - | -0.66 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | ABCL | 0.00 | 11.77 | 8.90 |
| 2025-03-21 | ABCL | 0.00 | 11.77 | 8.90 |
| 2025-03-24 | ABCL | 0.00 | 11.77 | 8.90 |
| 2025-03-25 | ABCL | 0.00 | 11.77 | 8.90 |
| 2025-03-26 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-03-27 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-03-28 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-03-31 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-01 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-02 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-03 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-04 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-07 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-08 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-09 | ABCL | 0.00 | 11.77 | 10.19 |
| 2025-04-10 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-11 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-14 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-15 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-16 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-17 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-18 | ABCL | 0.00 | 11.77 | 10.57 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ABCL
589 360 ]
Last Quarter Act. EPS
-0.11
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
-0.14
Insider Transactions
Institutional Transactions
11.77
Beta
0.41
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
6
Fair Value
Quality Score
41
Growth Score
35
Sentiment Score
78
Actual DrawDown %
96.6
Max Drawdown 5-Year %
Target Price
10.33
P/E
Forward P/E
PEG
P/S
25.01
P/B
0.68
P/Free Cash Flow
EPS
-0.55
Average EPS Est. Cur. Y
-0.66
EPS Next Y. (Est.)
-0.59
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-564.81
Relative Volume
0.7
Return on Equity vs Sector %
-35.4
Return on Equity vs Industry %
-22
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ABCL
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ABCL
589 450 ]
AbCellera Biologics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 596
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
stock quote shares ABCL – AbCellera Biologics Inc. Stock Price stock today
news today ABCL – AbCellera Biologics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABCL – AbCellera Biologics Inc. yahoo finance google finance
stock history ABCL – AbCellera Biologics Inc. invest stock market
stock prices ABCL
premarket after hours
ticker ABCL
fair value insiders trading